Inactive Instrument

Cubist Pharmaceuticals Inc Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

10/12/14	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
10/12/14	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

10/12/14	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
10/12/14	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE
09/12/14	Merck : to take on superbugs with Cubist Pharma buy	RE
09/12/14	AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	RE
09/12/14	Apple : S&P 500 posts worst day since Oct; energy shares sink	RE
09/12/14	Cubist Pharmaceuticals : options unusually active before Merck deal	RE
06/12/14	Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	RE
21/05/13	Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	RE

14/01/15	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	BU
20/12/14	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	BU
10/12/14	Cubist Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Cubist Pharmaceuticals Inc.	PR
09/12/14	Cubist Pharmaceuticals : Comments on CUBICIN Patent Litigation	BU
09/12/14	CUBIST PHARMACEUTICALS : ALERT: Johnson & Weaver, LLP Investigates the Fairness of Price and Process in Proposed Sale of Cubist Pharmaceuticals, Inc. to Merck	BU

21/12/14	Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen
21/12/14	Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées
10/12/14	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin
09/12/14	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars
09/12/14	Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète

Manager	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	01/01/1997

Director	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	72	01/09/2006
Kenneth J. Martin BRD	Director/Board Member	72	25/09/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENERON PHARMACEUTICALS, INC.	-1.67%	-4.78%	+37.02%	-4.42%	79.3B
CSL LIMITED	-0.90%	+2.39%	-18.98%	-35.69%	59.21B
MODERNA, INC.	-3.35%	-4.92%	+463.91%	+21.22%	55.09B
SAMSUNG BIOLOGICS CO.,LTD.	-6.78%	-4.19%	-4.50%	+28.86%	49.86B
UCB	-2.43%	-2.35%	+8.03%	+163.45%	47.9B
BIOGEN INC.	-1.35%	+0.79%	+64.72%	-17.56%	32.28B
INCYTE CORPORATION	-2.64%	-2.69%	+48.59%	+91.84%	25.21B
INNOVENT BIOLOGICS, INC.	-0.09%	+4.98%	+18.59%	+209.35%	23.87B
SWEDISH ORPHAN BIOVITRUM AB	-0.34%	+1.35%	+60.10%	+122.64%	16.89B
Average	-1.83%	-1.20%	+75.28%	+64.41%	43.29B
Weighted average by Cap.	-1.98%	-2.05%	+82.91%	+43.10%